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Abstract
Background: The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find
proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of
new medications is a time-consuming procedure, and not viable in a global emergency, such as the one we are
facing.
Main Body: Drug repurposing/repositioning, a strategy effectively employed in cancer treatment, can represent a
valid alternative. Most drugs considered for repurposing/repositioning in the therapy of the COVID-19 outbreak are
commercially available and their dosage and toxicity in humans is well known, due to years (or even decades) of
clinical use. This can allow their fast-track evaluation in phase II–III clinical trials, or even within straightforward
compassionate use.
Several drugs being re-considered for COVID-19 therapy are or have been used in cancer therapy. Indeed, virus-
infected cells are pushed to enhance the synthesis of nucleic acids, protein and lipid synthesis and boost their
energy metabolism, in order to comply to the “viral program”. Indeed, the same features are seen in cancer cells,
making it likely that drugs interfering with specific cancer cell pathways may be effective as well in defeating viral
replication.
Short Conclusion: To our knowledge, cancer drugs potentially suitable for facing SARS-CoV-2 infection have not
been carefully reviewed. We present here a comprehensive analysis of available information on potential candidate
cancer drugs that can be repurposed for the treatment of COIVD-19.
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Background
The coronavirus disease 2019 (COVID-19), a mild-to-
severe respiratory illness associated with symptoms
(fever, cough and shortness of breath), is caused by
severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). The very limited time allowed to face
the COVID-19 pandemic, as well as its severity,
imposes an unwavering commitment – from the
scientific community – to find proper therapeutic
approaches.
As for several infectious diseases, vaccination will
likely able to generate a safe, long-lasting protection
from SARS-CoV-2 infection, but this approach is not
suitable for the current COVID-19 outbreak. As an
alternative, antiviral drugs, or modulators of the host
immune response can be considered. However, synthesis
and full investigation - from preclinical studies to phase
III trials - of new medications is a time-consuming pro-
cedure, and is not viable in a global emergency, such as
this.
Conversely, drug repurposing/repositioning, a strategy
effectively employed in cancer treatment [1–3], can
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: marco.paggi@ifo.gov.it
3Cellular Networks and Molecular Therapeutic Targets, Proteomics Unit,
IRCCS – Regina Elena National Cancer Institute, Rome, Italy
Full list of author information is available at the end of the article
Ciliberto et al. Journal of Experimental & Clinical Cancer Research           (2020) 39:86 
https://doi.org/10.1186/s13046-020-01590-2
represent a valid alternative, provided that suitable medi-
cations are selected among the enormous number of po-
tential, already synthesized, and often already clinically
employed, compounds.
Drug repurposing has already been suggested for spe-
cific drugs in the treatment of the current COVID-19
outbreak [4–9]. Most drugs considered for repurposing/
repositioning in the therapy of the COVID-19 outbreak
are commercially available and their dosage and toxicity
in humans is well known, due to years (or even decades)
of clinical use. This can allow their utilization in faster
and less expensive phase II–III clinical trials, or even
within straightforward compassionate use.
In particular, a remarkable number of drugs re-
considered for COVID-19 therapy are or have been used
in cancer therapy. This should not be surprising if we
consider that virus-infected cells are pushed to enhance
the synthesis of nucleic acids, protein and lipid, and
boost their energy metabolism, in order to comply to the
“viral program”. Indeed, the same features are seen in
cancer cells, making it likely that drugs interfering with
specific cancer cell pathways may be effective as well in
defeating viral replication.
To our knowledge, cancer drugs potentially suitable
for facing SARS-CoV-2 infection have not been exhaust-
ively reviewed. In order to make a rational and effective
choice of drugs amenable of repurposing for the therapy
of COVID-19, we can elaborate existing data, from
experimental and translational research, clinical trials,
anecdotal reports and other published information.
We present here a comprehensive analysis of available
information on potential candidate cancer drugs that
can be repurposed for the treatment of COIVD-19.
Main text
Potentially suitable drugs for repositioning are essentially
those affecting signal transduction, synthesis of macro-
molecules and/or bioenergetic pathways, those able to
interfere with the host immune response, in particular,
the life-threatening cytokine storm associated with
severe COVID-19 and finally antiviral compounds are
occasionally effective in fighting cancer (Table 1. Please
note that research in the field is growing, and therefore
the list may be incomplete at the time of publication). A
single molecule can present more than one of the above-
mentioned mechanisms. Drugs and their mechanism of
action in relation to SARS-CoV-2 infection and host
response are depicted in Fig. 1.
Drugs interfering with signal transduction and/or
bioenergetics pathways
Rapamycin and derivatives
Rapamycin (sirolimus) has a long history of reposi-
tioning. It was first used as an antifungal, followed by an
immunosuppressive agent in organ-transplanted patients
and, more recently, also as an anticancer agent [2, 10].
Its cellular target has been named mTOR (mammalian
Target Of Rapamycin) after the name of the compound
itself, showing specific activity toward the mTORC1
complex [11]. Rapamycin is also effective in the therapy
of the autoimmune lymphoproliferative syndrome [12].
Rapamycin decreases mTOR phosphorylation
(mTORC1) [13], causing a downstream perturbation of
this signal transduction pathway. The consequent cata-
bolic inhibition and ATP shortage evokes the activation
of AMPK [14] and of its substrate ACACA, promoting
autophagy, a physiological procedure through which
Table 1 Old and new drugs tested or used in the oncological setting and potentially useful in COVID-19 therapy
Drug MoA
Rapamycin and
derivatives
Immunosuppressant; PI3K/mTOR inhibitor; inhibitor of viral replication
Chloroquine and
derivatives
Antimalarial; broad spectrum anti-infective agent; interferent with protein post-translational processes; autophagy inhibitor;
MAPK inhibitor; inhibitor of pro-inflammatory cytokines
SI113 SGK1 inhibitor
Tocilizumab MoAb targeting IL-6R, thus contrasting cytokine storm and fibrotic degeneration
Sarilumab MoAb targeting IL-6R, thus contrasting cytokine storm and fibrotic degeneration
Emapalumab plus
anakinra
MoAb targeting IFN-γ plus IL-1R antagonist
Monalizumab MoAb targeting NKG2A
BCG Tuberculosis prevention; inhibition of a TGF-β1-mediated EMT
Lopinavir plus ritonavir Viral Protease inhibitors approved for HIV treatment
Ribavirin Viral RNA synthesis inhibitor; RdRp inhibitor
Remdesivira Viral RNA polymerase inhibitor
BCG Bacillus Calmette-Guérin, EMT Epithelial-to-mesenchymal transition; MoA Mechanism of Action; MoAb Mono- clonal antibody; RdRp RNA-dependent
RNA polymerase
aNot used in oncological settings
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cells recycle old organelles or damaged proteins in order
to provide an alternative energy supply [15, 16].
mTOR inhibition counteracts viral replication and im-
proves outcomes in patients infected by Andes virus
[17], HCV [18], Middle-East respiratory syndrome cor-
onavirus (MERS-CoV) [19] and H1N1 pneumonia [20].
In addition, rapamycin (alone or in combination with ac-
tinomycin D) has been recently proposed to interfere
with the SARS-CoV-2 interactome in a systems
pharmacology-based network medicine platform [5]. As
specified above, rapamycin also presents immunosup-
pressant activity, which could be relevant in mitigating
the SARS-CoV-2-induced inflammatory response.
There are some rapamycin derivatives available, e.g.
temsirolimus, everolimus and ridaforolimus, which dis-
play slightly different pharmacokinetic characteristics
and may be worth evaluation in the treatment for
COVID-19. Among these, ridaforolimus has been tested
in phase II clinical trial compared with progestin or in-
vestigator choice chemotherapy in advanced endometrial
carcinoma showing encouraging results, but elevated
toxicity, confirming the significance of the mTOR path-
way in these neoplasms [21].
Chloroquine and hydroxychloroquine
Chloroquine (CQ) is a drug characterized by several de-
cades of clinical use due to its well-renowned preventive
and curative antimalarial activity. More recently, CQ has
attracted the oncologists for its ability of interfering with
the late stages of autophagy, by producing cytoplasmic
accumulation of non-functional autophagic vesicles [22].
Both normal and cancer cells utilize autophagy for ener-
getic purposes, but cancer cells, due to their higher en-
ergy requirements, rely more actively on autophagy,
Fig. 1 SARS-CoV-2 replication, host response and interfering drugs. The drugs able to counteract the processes underlying SARS-CoV-2 replication
and consequent host response, and their sites of action are shown. PBMC = Periferal Blood Mononucleate Cells
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especially after being stressed by radio- or chemotherapy
[23–25]. Therefore, the association of first-line thera-
peutic approaches in cancer patients with autophagy in-
hibitors has been largely investigated [26, 27] and
suggested [26–28] and clinically investigated in clinical
trials, mainly in CNS tumors [29–31].
CQ also possesses broad anti-infective and anti-viral
properties [32], especially against flaviviruses, retrovi-
ruses and coronaviruses [33]. Indeed, CQ can inter-
fere with sialic acid biosynthesis, compromising the
post-translational modifications of the transmembrane
viral binding proteins [34, 35], thus impairing viral
penetration inside the cell. Indeed, interaction be-
tween SARS-CoV-2 and the membrane receptor
angiotensin-converting enzyme 2 (ACE2), maximally
expressed in lung alveolar epithelial cells, enterocytes
of the small intestine, Leydig cells and Sertoli cells,
strongly depends upon glycosylation [36]. CQ also in-
duces alkalization of endosomes, thus inhibiting endo-
cytosis of the viral particles and their enzymatic
degradation by proteases [37–39], an essential step
for the release of functional viral nucleic acid [33].
Furthermore, CQ improves viral antigen presentation
and thus enhances T-cell-mediated immunity [40].
Another major advantage of CQ is its ability to modu-
late the inflammatory response and reduce the synthesis
of pro-inflammatory cytokines. This molecule has been
used since decades in the treatment of abnormal inflam-
matory responses (sarcoidosis) and autoimmune disor-
ders (rheumatoid arthritis; lupus erythematosus). The
ability of CQ to reduce cytokine immune response [41]
could be functional in governing the cytokine storm as-
sociated with COVID-19 [42].
A mechanism similar to the one described for the in-
hibition of the autophagosomes could be speculated to
impair formation and release of virion-containing vesi-
cles by infected cells.
Very recently, CQ has been used in COVID-19 therapy
at the dose of 500 mg/day with favorable results [39],
butother studies demonstrate high toxicity and scarce ef-
fect of either CQ [43] or its analogue hydroxychloro-
quine (HCQ) [44, 45] in treating patients with severe
COVID-19.
Since autophagy is regulated by the interplay between
mTOR [46] and AMPK [15], the use of CQ in combin-
ation with drugs able to interfere with these pathways
should be carefully evaluated.
CQ has a well-known safety profile, but it is associated
with toxic retinopathy, renal and cardiac toxicity, which
occur when the safe dose is exceeded. HCQ possesses
slightly different pharmacokinetic properties and dis-
plays less overall toxicity. HCQ is commercially available
worldwide, which it is not the case for CQ, whose distri-
bution has been discontinued in some countries [47].
Both CQ and HCQ are being considered for use to pre-
venting COVID-19 in SARS-CoV-2 post-exposure and
long-term prophylaxis [48].
SI113
SI113 is a small molecule able to inhibit the activity of
SGK1, an AKT-related kinase involved in the PI3K/
mTOR pathway and in EMT [49]. This kinase plays a
pivotal role in cancer proliferation and drug resistance
[49, 50] and is sensitive to the small molecule SI113
[51], which is thus able to inhibit cancer cell growth
in vitro and in vivo [52, 53] via a multifaceted mechan-
ism of action, including inhibition of the PI3K/mTOR
pathway and stimulation of autophagy [54].
Infection by MERS-CoV, a cognate of SARS-CoV-2,
induces a massive inflammatory response, possibly re-
lated with fibrosis, mainly via the upregulation of the T
helper (Th) 1 and Th17 cells [55]. Of note, IL-17-
producing Th cells are induced by the activity of SGK1
[56]. Additionally, experimental models of inflammatory
bowel disease showed the role of Th17 and SGK1 as me-
diators of the Th17 switch [57]. Therefore, SI113 could
deserve evaluation in the prevention of the cytokine
storm-induced lung fibrosis.
It should be noted that SI113 has never been used in
humans, but it is effective in reducing tumor growth in
cancer-bearing mice, appearing also well tolerated and
non-toxic [52, 53]. Thus, SI113 cannot be considered a
repurposed drug, although preclinical models indicate it
as potentially effective in COVID-19 therapy. We in-
cluded this drug in the present manuscript for the sake
of completeness.
Immunomodulatory medications
Tocilizumab
This compound is a humanized monoclonal antibody
(MoAb) targeting interleukin-6 receptor (IL-6R).
Pharmacology, pharmacokinetics, clinical efficacy, safety,
and role of tocilizumab in rheumatoid arthritis (RA) are
well-established [58] and possibly due also to its effect
on the AKT/mTOR pathway [59]. Tocilizumab has also
been approved for the treatment of the cytokine storm
associated with cancer immunotherapy [60] or, more
often, with CAR-T therapy [61, 62]. This MoAb does
not have direct antiviral effects, but effectively contrasts
the massive cytokine release syndrome displayed in se-
vere COVID-19 by antagonizing the binding of IL-6, one
of the cytokines most involved in this process, to its re-
ceptor [58]. After the first report of the effectiveness of
tocilizumab in restraining the cytokine storm deriving
from SARS-CoV-2 infection [63], this drug is currently
under evaluation in a multicenter phase II clinical inves-
tigation in Italy on its efficacy and safety in patients with
COVID-19 pneumonia [64]. The FDA has approved a
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phase III randomized, double-blind, placebo-controlled
study to assess the effectiveness of tocilizumab in hospi-
talized patients with severe COVID-19 pneumonia [65];
in addition an increasing number of clinical trials involv-
ing the use of this drug in the treatment of COVID-19
are ongoing (https://clinicaltrials.gov/).
Sarilumab and Emapalumab
Sarilumab is an anti-IL-6Rα MoAb approved for
moderate-to-severe rheumatoid arthritis [66] with a well-
defined role also in blocking IL-6 action in cancer [67],
while emapalumab, directed toward interferon (IFN)-γ, is
used in the therapy of hemophagocytic lymphohistiocyto-
sis [68, 69] and is employed in combination with anakinra,
an IL-1R antagonist, in RA patients [70]. As tocilizumab,
also sarilumab and emapalumab can effectively counteract
the massive cytokine release related with SARS-CoV-2 in-
fection. Agenzia Italiana del Farmaco (AIFA) approved the
use of either sarilumab or emapalumab in phase II–III
clinical studies involving hospitalized patients with
COVID-19 pulmonary complications, with the aim to
counteract the cytokine storm [64].
Monalizumab
Monalizumab is a MoAb directed toward NKG2A
(CD94), a receptor for the recognition of MHC class I
HLA-E molecules. NKG2A is gaining relevance as a key
player in cancer-mediated immune checkpoint blockade
and its neutralization by monalizumab restores the host
immune response toward cancer [71]. Monalizumab is
under clinical investigation in advanced gynecologic ma-
lignancies [72]. Interestingly, NKG2A appears overex-
pressed in cytotoxic T lymphocytes and natural killer
cells in SARS-CoV-2-infected patients [73, 74], where it
may reestablish the host immune response and increase
survival in patients with severe pneumonia.
Bacillus Calmette-Guérin
Bacillus Calmette-Guérin (BCG), an invaluable tool for
vaccination against tuberculosis, has been widely used as
a concomitant therapeutic approach for lung cancer
[75], and is considered as an overall protection from
lung cancer incidence [76]. More recently, BCG has
been successfully used for the local treatment of inter-
mediate/high-risk bladder cancer [77].
BCG presents recognized immunomodulatory proper-
ties [78] and is associated with reduced risk of asthma
[79]. Immunization via BCG provides relief from airway
inflammation through the inhibition of a TGF-β1-
mediated epithelial-to-mesenchymal transition (EMT),
inhibiting the related remodeling of the respiratory tract
accompanied with loss of lung epithelial integrity and fi-
brotic evolution [80]. In the COVID-19 setting, epithelial
integrity of the respiratory tract is fundamental, since
permanent lung fibrosis is a serious risk for severe and
critically severe COVID-19 survivors [42]. Therefore,
BCG might reduce the risk of severe disease progression
and potentially reduce the mortality and disability rate.
Antiviral compounds
Clearly, some of the drugs under consideration for re-
purposing for COVID-19 therapy are antiviral com-
pounds, usually nucleoside analogues, i.e., small
molecules mimicking ribonucleosides or deoxyribonu-
cleosides able to inhibit viral replication after being in-
corporated within the viral nucleic acid sequence. These
drugs have been used since decades as antivirals,
although their clinical efficacy is often associated with
the onset of drug resistance. Some antiviral drugs show
interesting anticancer properties, being effective in inhi-
biting important signal transduction pathways, in vitro
and in vivo [81, 82].
Lopinavir plus ritonavir
The association of the protease inhibitors lopinavir and
ritonavir is an approved treatment for HIV treatment. It
is effective in restraining the growth of urological malig-
nancies in vitro, where induces endoplasmic reticulum
stress, mTOR inactivation and AMPK boosting [83].
The same drug combination has been also evaluated in
the treatment of cervical cancer patients [84].
The association between lopinavir and ritonavir is ef-
fective in reducing the risk of adverse clinical outcomes
and viral load in SARS patients [85]. On these bases, this
cocktail has been proposed for the treatment of COVID-
19, but a very recent clinical trial showed no benefits in
adult patients with severe disease [86].
Ribavirin
This drug is a guanosine analogue and RNA synthesis
inhibitor successfully employed in the therapy chronic
hepatitis C virus (HCV) infection [87]. As far as cancer
is concerned, this compound induces GTP depletion in
HeLa cervical cancer cells [88] and is effective in inhibit-
ing glioblastoma growth in vitro and in vivo in preclin-
ical models [81]. Along this line, the efficacy of ribavirin
in the oncological setting is being investigated in on-
going clinical trials in acute myeloid leukemia, oropha-
ryngeal squamous cell carcinoma, and breast cancer
[89]. Ribavirin is also endowed with COVID-19 anti-
RNA-dependent RNA polymerase (RdRp) activity [4].
Clinical trials are ongoing, based upon available data re-
garding dosage and toxicity derived from broad experi-
ence on the use of this drug as an anti- HCV compound.
Remdesivir
This compound is not cancer-related, but deserves to be
mentioned as a paradigmatic case of effective repositioning.
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It is a prodrug of an adenine analogue, thus a viral RNA
polymerase inhibitor, used during the Ebola outbreak [90].
Remdesivir has been found effective in vitro against SARS-
CoV-2 infection when administered in concomitance with
the antimalarial CQ (see above) [91] and in vivo in a pri-
mate model (rhesus macaque), either as prophylaxis or
therapy of MERS-CoV infection [92]. Presently, clinical tri-
als on remdesivir in COVID-19 are enrolling patients and
are supported by the National Institutes of Health (NIH)
[93], USA and AIFA, Italy [64]. Compassionate use of
remdesivir in COVID-19 patients in a single-arm clinical
trial gave positive preliminary outcomes [94], which appear
in contrast with the results published by another group
[95]. While the debate over the efficacy of this drug is still
open, according to the preliminary results reported in the
ACTT NIH clinical trial [93], the FDA has given remdesivir
an emergency use authorization restricted to patients af-
fected by severe COVID-19 [96].
Conclusions
COVID-19: a lesson to be learned. The SARS-CoV-2
pandemic has been generated by a new strain of the cor-
onavirus that has never previously been identified in
humans. This virus is phylogenetically close to SARS-
CoV, the causative agent of SARS. SARS-CoV-2, which
reached humans via a spillover process from other ani-
mal species, possesses a peculiar tropism for the airway
epithelium in humans, showing also elevated contagious-
ness and an extremely variable clinical course of its
infection.
The COVID-19 outbreak found the world definitely
unprepared to handle such a global emergency. Similar
concerns must be raised toward a potential novel strain
possibly responsible for future viral outbreaks, in order
not to replicate the extremely negative outcome of the
influenza A H1N1 1918–1919 “Spanish” pandemic [97].
To this end, it is mandatory to work prospectively to
produce or identify better antiviral drugs and prophylac-
tic/therapeutic MoAb therapies, as well as possibly tar-
geting vital pathogenic factors, such as, in the case of
SARS-CoV-2, Spike protein RBD [36, 98] or the main
protease Mpro [99]. In addition, a study on the immune
response of patients that have recovered from SARS-
CoV-2 infection could be of great interest, in line with
what was carried out for the Ebola survivors [100].
The forcedly limited number of drugs briefly de-
scribed in this review appear to act essentially
through selected mechanisms, i.e., a) inhibition of the
PI3K/AKT–SGK1/mTOR signaling cascade; b) inhib-
ition of the cytokine storm; and c) inhibition of viral
nucleic acid synthesis. The activation of the PI3K/
AKT–SGK1/mTOR pathway appears fundamental for
supporting the replication of various virus species in
the host [17–20] by boosting their energy metabolism
and reactive oxygen species production, especially in
the cells of the immune system [101, 102]. Therefore,
drugs able to interfere with mTORC1 signaling can
produce ATP shortage in the cells in which the virus
is replicating, characterized by an excess of energy re-
quirements. Such a metabolic pattern is reminiscent
of the peculiar setup of the energy metabolism in
cancer cells, i.e. Warburg effect [103, 104], where a
pivotal role is played by the PI3K/AKT–SGK1/mTOR
signaling cascade [10, 105, 106].
Given the above, it is not surprising that all the non-
specific antiviral drugs here described, i.e. the anticancer
drugs repositionable in COVID-19 therapy deal with en-
ergy metabolism and inflammation.
A set of the drugs described here, e.g. those with expli-
cit antiviral effect, can be preferred for the early stages
of SARS-CoV-2 infection, while those dedicated to
restraining the cytokine response – and without explicit
antiviral effect - should be employed, if necessary, at
later time points. Anyway, we should always consider
that, even if the medications discussed in this review are
safely in use in the clinics, the final decision for their ad-
ministration in COVID-19 for compassionate and urgent
use, when in the absence of validated clinical trials,
should be taken solely after collegial approval by the
clinical team taking care of the patient and under strict
clinical surveillance. Indeed, unpredictable toxic side ef-
fects can arise, possibly linked with the patient clinical
status or to the simultaneous administration of other
drugs.
Finally, an interesting evaluation on how COVID-19
pandemic will affect the clinical care in the seven com-
prehensive cancer centers of Cancer Core Europe is dis-
cussed in a timely paper [107]. The authors illustrate
appropriate guidelines that can transform this pandemic
into an opportunity, e.g. for the assessment of the clin-
ical effects of de-escalating anticancer regimens, forcedly
imposed in order to prevent or reduce iatrogenic neutro-
penia and lymphopenia.
We hope that these findings may pave the way for a
more comprehensive clinical experimentation on repur-
posing of ‘old’ drugs to the treatment of COVID-19, a
line of research sustained by scant funds but of prime
importance to face this new worldwide challenge.
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